파트너링 VIP 참석자 배포용 해외 참여기업 리스트 · 1 day ago · 파트너링 VIP 참석자 배포용 회사명 Tubepac SDN

파트너링 VIP 참석자 배포용 <해외 참여기업 리스트>

회사명 Tubepac SDN. BHD.

국가 Malaysia

홈페이지 https://tubepac.my

출품 품목

회사소개

국문

영문

"MANUFACTURE AND SUPPLY OF ALUMINIUM COLLAPSIBLE TUBE

Export Markets: SINGAPORE, TAIWAN, THAILAND, SRI LANKA, PAKISTAN

Details about Interest:EXPORT ALUMINIUM COLLAPSIBLE TUBE

Name/Type of Korean Companies Hope to Meet: PHARMACEUTICAL CREAMS

AND OINTMENTS MANUFACTURERS"

제품소개

국문

영문

ALUMINIUM COLLAPSIBLE TUBE, PRIMARY PACKAGING FOR PHARMACEUTICALS

CREAMS, OINTMENTS AND GELS.


회사명 PHARMANIAGA Manufacturing BERHAD

국가 Malaysia

홈페이지 www.pharmaniaga.com

출품 품목 PHARMACEUTICALS

회사소개

국문

영문

As Malaysia’s largest listed integrated pharmaceutical group, Pharmaniaga

Berhad has blazed a trail within the healthcare industry as a provider of quality

products and services. Listed on the Main Board of Bursa Malaysia and having

established itself as a leader in the local market, Pharmaniaga also has a growing

global presence.

Export Markets: BRUNEI, SINGAPORE, MYANMAR, HONGKONG, MACAU,

MALDIVES, SRILANKA, LAOS, PORTUGAL

Details about Interest: Biosimilar products including MABs and vaccine

Name/Type of Korean Companies Hope to Meet: Any biosimilar company

Trade History with Korean Companies: Partnership with Dong A ST and Wooshin

제품소개

국문

영문


회사명 MINH ANH COSMETIC MEDICINE Ltd.

국가 Vietnam

홈페이지 Ancarevietnam.com

출품 품목 Medical equipment

회사소개

국문

영문

"ORGANIC MINH ANH COSMETIC MEDICINE COMPANY LIMITED

- Main Products : Medical equipment

- Markets : EU - USA - Canada

- Company Introduction

: Organic Minh Anh Cosmetic Medicine Company Limited is accompany

operating

in the medicine and pharmacy field under the provisions of Vietnamese and

international laws from 2018. We have certification of quality meet all standards

of USA and EU.

We have 2 producing factories with producing capacity is 12.5 million pieces/day

- Year of Establishment : 2018

- Number of Employees : 500

- Annual Sales : 5,000,000 USD"

제품소개

국문

영문 Medical equipment : mask, gown, protective suit


회사명 VINA SAMEX., JSC

국가 Vietnam

홈페이지 vinasamex.com

출품 품목 Cinnamon, Star Anise, other spices

회사소개

국문

영문

"VIETNAM STARANISEED CASSIA MANUFACTURING AND EXPORTING JOINT

STOCK COMPANY (VINA SAMEX., JSC)

- Main Products: Cinnamon, Star Anise, other spices (ginger, turmeric, chilli,

pepper, garlic)

- Export Markets: Korea, Japan, EU, USA, Asia, ...

- Year of Establishment: 2012

- Number of Employees: 70

Specific Items to Import/Import : Want to export Cinnamon, Star Anise, other

spices (ginger, turmeric, chilli, pepper, garlic)

Trade History with Korean Companies: Sejun food; Asia Fairtrade Network"

제품소개

국문

영문

"Cinnamon

- Cinnamon is a perennial tree with the height of 10-20m, a shaggy and

chapped outer bark, a branched trunk and brown branches. Cinnamon tree can

grow in the wilderness or be cultivated into forest and forest cluster by seeding

or layering process.

Star Anise

- Star anise forests mainly reside at the height of about 200-600m, with annually

average temperature of about 18-220C, directly affected by the Seasonal North-

East wind.

Sustainable Quality: Cinnamon and Star anise are manufactured, collected and

processed according to scientific process from seedling to finished products,

strict control to achieve the highest quality in accordance with international

standard."


회사명 An Binh pest control

국가 Vietnam

홈페이지 dietcontrung24h.com.vn

출품 품목 Pest control services

회사소개

국문

영문

"Year of Establishment: 2015

Number of Employees: 50

Annual Sales : USD 1.250.000

Export Market: Japan, Taiwan

Details about Your Interest : Export and joint venture"

제품소개

국문

영문 Artemisia vulgaris, Houttuynia cordata , Portulaca oleracea , Momordica

cochinchinensis


회사명 THIENBINH Nature Herbs

국가 Vietnam

홈페이지

출품 품목 Artemisia vulgaris , Houttuynia cordata , Portulaca oleracea , Momordica

cochinchinensis ,

회사소개

국문

영문

"Year of Establishment: 2015

Number of Employees: 50

Annual Sales : USD 1.250.000

Export Market: Japan, Taiwan

Details about Your Interest : Export and joint venture"

제품소개

국문

영문

Artemisia vulgaris, Houttuynia cordata , Portulaca oleracea , Momordica

cochinchinensis


회사명 BRIAN IR MEDICAL Company Limited

국가 Vietnam

홈페이지 www.duocthiennhien.com

출품 품목 ©Medical Product distributor

회사소개

국문

영문 Medical Product distributor

제품소개

국문

영문

http://www.duocthiennhien.com/


회사명 ANPO VIETNAM CO.,LTD

국가 Vietnam

홈페이지

출품 품목 Cosmetics, distributors, food

회사소개

국문

영문 Specific Items Want to Import: Cosmetic, foods

제품소개

국문

영문 Cosmetic/ Power tools


회사명 Cold Chain Technologies

국가 Sigapore

홈페이지 https://www.coldchaintech.com/

출품 품목 KoolTemp EndeavAir, KoolTemp EcoFlex96,

회사소개

국문

영문

At Cold Chain Technologies (CCT), we focus on understanding the unique

challenges experienced by each of the markets we serve. Our extensive thermal

packaging design and manufacturing experience enable us to provide problem

solving products and services to clients around the world in markets that include

pharmaceutical and biotech manufacturers, specialty pharmacies, third party

logistics (3PL) providers, and nutraceutical companies.

제품소개

국문

영문

"KoolTemp EndeavAir 1600L

The True Replacement for Active Solutions at a Fraction of the Cost!

Up to 144+ Hour Duration – 2.0°C–8.0°C, 15.0°C–25.0°C, and < -20.0 °C

Lowest Total Cost

41% cost savings vs active units

30% cost savings vs passive units

Universal Pack-Out – Simplified pack-out process takes less time

No Compromise – Payload height of 50” (127 cm)

Complete Confidence – Real-time visibility to system location and temperature

Worldwide Solution – Accepts US or Euro palletized payload

Maximum Operational Flexibility – Conditioned set-up trip lease

Lower CO2 Footprint – Reduce empty repositioning transport with

flexible unit configuration

KoolTemp EcoFlex 96

Ecology + Economy + Flexibility

Now Up to 5+ Days – Robust temperature performance against ISTA 7D

Universal Pack-Out– 2-8°C and 15-25°C (Frozen forthcoming)

Lightweight with Optimal Sizing – Reduce freight costs with increased payload

efficiency

Sustainable & Recyclable – Reusable shipping system with recyclable single-use

components

Maximum Operational Flexibility– White glove, conditioned set-up delivery offers

complete confidence

Affordable Custom Reusable Solutions – Smart, thermal packing designs

available to your specs"


회사명 AiVF (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.aivf.co

출품 품목 Algorithm / AI solution

회사소개

국문

"AiVF 는 체외수정 (IVF) 프로세스를 위한 AI 기반 의사 결정 플랫폼을 개발합니다.

AiVF 는 Cornell Weill Medicine, IVI Valencia, Assuta Medical Center 및 London's

Women's Clinic 과 같은 세계적인 기관과 협력하고 있으며, IVF 클리닉/실험실에서

최상의 배아를 선택할 수 있도록 돕습니다."

영문

"AiVF develops an AI driven decision platform for the in-vitro fertilization (IVF)

treatment process. The company was founded in 2018 by three IVF industry

veterans, Daniella Gilboa (CEO who was an embryologist), Prof. Eyal Schiff (Sheba

Medical Center) and Prof. Danny Seidman (Assuta Medica Center) who saw that

IVF can benefit from application of data science and artificial intelligence in

order to increase success rates, efficiency and expand access to IVF.

AiVF is collaborating with world leading organizations such as Cornell Weill

Medicine, IVI Valencia, Assuta Medical Center and the London's Women's

Clinic. Our first application enables clinics/labs evaluate and choose the best

embryos and eventually will apply our technology to other processes within the

IVF clinic/lab.

We alo have a stellar and active advisory board including Prof. Dan Ariely, Dr.

Eyal Gruss (AI expert) and leading IVF KOLs Dr. Nikica Zaninovic (Cornell Weill

Medicine), Marcos Meseguer (IVI Valencia), Prof. Barry Behr (Stanford University)

and Prof. Lee Shulman (Northwestern University)."

제품소개 국문

"출품품목-알고리즘 / AI 솔루션

AiVF 의 소프트웨어 플랫폼은 IVF 클리닉/실험실에 """"디지털 조언"""" 역할을 하여

배아를 평가 및 선택 수행을 합니다.

현재에는 발생학자의 경험과 배아의 시각적 평가를 기반으로 선별이 수행되어

주관적이고 시간이 비교적 오래 걸리는 반면, 플랫폼은 자동화이며 전 과정의

효율성을 증가시킵니다. 현재 IVF 의 평균 성공률은 약 25%이지만, AiVF 의 AI

플랫폼을 적용한다면 성공률을 높일 수 있는 기회가 주어집니다."

영문

"Product Category-Algorithm / AI solution

AiVF's software platform acts as a """"digital advisor """" for the IVF clinics/lab.

Its first application will be in performing embryo evaluation/selection. Embryo

selection is currently done based on the embryologist's experience and visual

assessment of the embryo. Our platform automates and increases the efficacy of

this process which is currently subjective and time consuming. The current

average success rate of IVF is about 25% and there is a lot of opportunity to

increase this via the application of AiVF's AI platform. Our plan is to expand our

platform's functionality to other junctures in the IVF treatment process.

Our product is currently being tested in beta site clinics in Europe and the US. "


회사명 Carmel Diagnostics ltd. (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.carmel-diagnostics.com

출품 품목 Medical Device

회사소개

국문

"Carmel Diagnostics 는 건강과 질병의 바이오마커 및 핵심 진단 매개 변수인

생물학적 액체의 산화스트레스 (OS) 를 측정하는 혁신적인 방법을 개발한 의료

기술 회사입니다. 이 OS 매개 변수는 TCL (ThermoChemiLuminescence) 에 의해

측정됩니다.

Carmel 의 주요 제품은 IVF 과정의 배아 선택입니다. "

영문

Carmel Diagnostics is a medtech company who developed an innovative method

for measuring Oxidative Stress (OS) of a biological liquid, a recognized

biomarker of health and disease and a key diagnostics parameter. This OS

parameter is measured by TCL (ThermoChemiLuminescence), an advanced yet

simple technology. Carmel’s lead product is Embryo Selection in IVF process.

Carmel won the prestigious Phase-2 grant from Horizon2020, planning market

launch in 2019. It has an experienced, motivated team.

제품소개

국문

출품품목-의료기기

Fertissimo TCL Analyzer 는 IVF 시장을 위한 혁신적인 비침습적 배아 선택

시스템으로, IVF 시술의 성공률을 최대 20% 증가시켜줍니다. 2019 년 10 월 CE

인증을 받았으며, 차세대 제품이 임상 검증을 거쳐 2021 년에 출시 될 예정입니다.

이 제품은 심부전 환자에 대한 위험 계층화, AMD 의 진단 및 치료 모니터링,

파킨슨과 알츠하이머의 조기 진단 등과 같은 다른 분야에서도 응용 가능합니다."

영문

Producat Category-Medical Device

Fertissimo TCL Analyzer is an innovative, noninvasive embryo selection system

for the IVF market, offering up to 20% increase in successful IVF pregnancies.

Effective embryo viability assessment significantly improves success rate and

reduces the risk of multiple births. Successful clinical trials were performed in

Israel and in Europe (Spain). New generation of the product will soon start

extensive clinical validation and will be launched in 2021. CE Mark was granted

in October 2019. Business model is pay-per-test using the disposable and

software control, while the devices will be sold with nominal price.

Accurate, scientifically based, NON-INVASIVE solution to the embryo selection

application - the ""holy grail"" of the IVF process.- Low cost device, minimal

initial investment for the users- Very friendly,easy-to-use system- Optional

oocyte quality testing- Examining the patient's probability for pregnancy - not

just on embryo base- Testing cryopreserved - thawed embryos. The device can

also be used for additional applications such as: Risk stratification for Heart

Failure patients, Diagnosis and treatment monitoring of AMD, early diagnosis of

Parkinson and Alzheimer's, assessment of damage in TBI - Traumatic Brain injury.

We base our solution on using oxidative stress as a novel efficient biomarker.

The potential market is each and every IVF clinic in the world. There are more

than 3000 clinics world wide and well over 2 Millions IVF procedures (Cycles)

every year with expected growth of 5-7%. The market size of embryo selection is

500M$. The product is needed world wide in every IVF clinic. Improving success

rate in the procedure is very important considering high cost, pain and stress to

the patients and couples in general.


회사명 Fertigo Medical Ltd. (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.fertigo-medical.com


회사소개

국문 ©IVF 치료 성공률 향상

영문 Improve the success rate in IVF treatments

제품소개

국문

"출품품목-의료기기

자궁의 발달을 모니터링하고 배아 이식을 위한 최적의 타이밍을 예측하는 소형

자궁경을 개발합니다."

영문

Product Category-Medical Device

A mini-hysteroscope to monitor the uterus evolution and predict the optimal

timing for embryo transfer


회사명 eHealth Ventures (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.ehealthventures.com


회사소개

국문

eHealth Ventures 는 디지털헬스 기업들의 인큐베이터이자 투자자로, Maccabi 를

포함한 주요 이스라엘 HMO 들과, Cleveland Clinic 및 Amgen 등, 다국적 의료

서비스 제공 업체, 산업 및 금융 전문가와 파트너쉽을 맺고 있는 선도적인 초기

단계 벤처투자자입니다.

영문

eHealth Ventures is an incubator and investor in Digital Health companies. We

are Israel's leading early stage investor in the sector - a partnership of

multinational healthcare providers, industry and financial experts including

Maccabi, the leading HMO in Israel, the Cleveland Clinic and Amgen. We have

reviewed over 1,200 ventures and invested in 12 disruptive companies.

제품소개

국문


eHealth Ventures 는 1,200 여개의 벤처를 검토하였고, 현재 12 개 회사의

포트폴리오를 가지고 있습니다. 자세한 내용은 http://www.ehealthventures.com/

를 참고해주십시오."

영문 "Product Category-Software-Application

We have a portfolio of 12 companies. See www.ehv.health for details. "


회사명 Geneyx Genomex Ltd (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.geneyx.com

출품 품목 Software-Application

회사소개

국문

Geneyx 는 스마트 관리, 자동화 된 병렬 파이프라인, 분석, 지식 기반 해석 및 전

세계 병원과 실험실에서 수집 된 임상 유전학 데이터 공유를 위한 클라우드 기반

플랫폼을 개발하였습니다.

영문

Geneyx developed a cloud-based platform for smart management, automated parallel pipeline, (fastq to VCF), analysis, knowledge-based interpretation, and sharing of clinical genetics data collected from hospitals and labs worldwide. Geneyx ensures freedom-to-operate for research, by providing access to a wealth of clinical genetics data of high quality, reliability, diversity, and compliance with strict privacy regulation. Geneyx provides the management and analysis software suite for hundreds of genetic labs while encouraging them to grant access to this precious data with sophisticated informed consent management and gold-standard privacy and security measures. Geneticists in top pediatric hospitals use our platform for analysis and interpretation of clinical genetics data, reporting higher diagnostic yields, supporting the identification of novel genes and novel variants, and their associations with clinical phenotypes.

제품소개

국문

출품품목-소프트웨어-앱

Geneyx Data 는 병원/실험실 모든 유전자 데이터의 효율적인 저장, 분석 및 관리를

위한 혁신적인 올인원 플랫폼을 제공하여 통합 된 임상 유전 데이터 자산의 가치를

극대화 할 수 있습니다.

Geneyx Analysis 는 신속하게 더 높은 진단율로 신속한 분석, 해석 및 보고를 위한

새로운 지식 기반 툴박스입니다.

영문

"Product Category-Software-Application ""Geneyx Data"" provides hospitals' labs with an innovative, all-in-one platform for ef?cient storage, analysis, and management of all genetic data, enabling to maximize the value of the integrated clinical-genetic data assets. ""Geneyx Analysis"" is a novel, knowledge-based toolbox for rapid analysis, interpretation, and reporting with a rapidly higher diagnostic yield. ""Geneyx research"" secure access to high-quality genetic data Freedom to operate (built-in consent management) - Unlimited computation capabilities - Enabling worldwide collaboration

“Geneyx tests” offer patients, new genetic reports. 1000+ health categories and

conditions, medication effects, and health traits, Unmatched by any other report, they will gain knowledge allowing them to take a proactive approach to live a longer and healthier life."


회사명 Augmentiqs (이스라엘경제무역대표부)

국가 Israel

홈페이지 ©www.augmentiqs.com

출품 품목 Research tool

회사소개

국문

Augmentiqs 는 기존 광학 현미경을 디지털 및 스마트 장치로 변환하는 기술을

개발합니다. 전 세계적으로 peer review, frozen section 및 WSI 가 지원할 수 없는

기타 샘플에 대한 실시간 원격 상담을 위해 병리학자들이 사용하고 있으며, 현재

국내 제약 회사에서도 AI 개발, 데이터 수집 및 기타 디지털 기능을 위해 사용하고

있습니다.

영문

"Augmentiqs develops technology for transforming the existing light microscope

into a digital & smart device.

Augmentiqs is currently being used by Korean pharmaceutical companies for AI

development, data collection and other digital capabilities.

Throughout the world, Augmentiqs is being used by pathologists for real-time

remote consultations of peer review, frozen sections, and other samples that WSI

cannot support. "

제품소개

국문

"출품품목-연구도구

Augmentiqs 는 기존 아날로그 현미경에서 디지털 병리학 기능을 지원합니다.

- 증강현실 접안 렌즈

- 실시간 원격병리진단

- AI 훈련 및 효율적 사용

- 현미경 작업 흐름의 감사 추적"

영문

"Augmentiqs enables digital pathology functionality from the existing analog

microscope.

Augmented Reality Eyepiece

Real Time Telepathology

AI training and deployment

Audit Trail of Microscopy Workflow

More"


회사명 BSP Medical (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.bspmedical.com


회사소개

국문

BSP Medical 은 혁신적인 생물의학 기술 기업으로, 허혈성심장질환 (IHD) 의

비침습적 모니터링 및 진단을 위한 기기를 개발하였습니다. BSP 는 고주파

영역에서 ECG 신호 분석을 위한 HyperQ 를 개발하였고, 이 솔루션은 여러 국가의

파일럿 프로그램 및 임상 연구에서 테스트 되었으며 허혈성심장질환의 감지 및

모니터링을 위한 타 비침습적 수단보다 우수한 임상 성능을 입증했습니다.

영문

"BSP Medical is an innovative biomedical technology Israeli company,

revolutionizing non-invasive monitoring and diagnosis of ischemic heart disease

(IHD), the deadliest condition in the world.

BSP was founded by seasoned entrepreneurs, researchers in the field of

biomedical data processing. It is a wholly-owned subsidiary of ICB, a publicly

traded company on the Tel Aviv Stock Exchange.

Based on decades of scientific research by its founders and technologists, BSP

has developed the HyperQ, a groundbreaking, proprietary technology for the

analysis of ECG signals in the high frequency domain. BSP's solutions have been

tested in clinical studies, pilot programs and clinical use around the world and

have demonstrated superior clinical performance over any other non-invasive

means for the detection and monitoring of ischemic heart disease.

A unique offering of BSP's technology for pharma companies lies in its ability to

provide an accurate, non-invasive means for a quantitative indication of ischemic

burden and approaching ischemic events, serving as an essential, high-value tool

for drug development in the cardiovascular domain.

BSP's HyperQ products have gained regulatory approval and clearance by CE,

FDA and CFDA (China). HyperQ platform technology is implemented in various

clinical settings including stress testing, resting ECG, bed-side monitoring,

implantable cardiac devices and wearable solutions. "

제품소개

국문

"출품품목-의료기기

HyperQ 는 병의원부터 종합병원까지 모든 등급의 의료시설에서 상용할 수 있으며,

급부상하는 헬스케어 시장에 대응할 수있는 상품 플랫폼입니다. HyperQ 는 주요

심혈관 사건 (MACE) 를 예측할 수 있는 고유의 역량을 갖추었으며, 심전도시스템의

휴지기 중에도 급성 관상동맥질환을 조기 감지할 수 있습니다. 이 제품은 CE, FDA

및 CFDA 승인을 받았습니다."

영문

"Based on decades of scientific research by its founders and technologists, BSP

has developed the HyperQ product line, a groundbreaking, proprietary line of

products for the analysis of ECG signals in the high frequency domain.

BSP's products have been tested in clinical studies, pilot programs and clinical

use around the world, demonstrating superior clinical performance over any

other non-invasive means for the detection and monitoring of ischemic heart

disease.

A unique offering of BSP's technology for pharma companies lies in its ability to

provide an accurate, non-invasive means for a quantitative indication of ischemic

burden and approaching ischemic events, serving as an essential, high-value tool

for drug development in the cardiovascular domain.

BSP's HyperQ products have gained regulatory approval and clearance by CE,

FDA and CFDA (China). HyperQ platform technology is implemented in various

clinical settings including stress testing, resting ECG, bed-side monitoring,

implantable cardiac devices and wearable solutions. "


회사명 ©Beyeonics Surgical (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.beyeonics.com


회사소개

국문

"Beyeonics 는 2018 년 Elbit Systems 를 통해 설립 된 외과 중심의 시각화 솔루션을

개발하는 의료기기 업체입니다.

Beyeonics 가 최초로 개발한 시스템인 Beyeonics One - 시각화 플랫폼은 수술실

(OR) 시각화의 표준을 재정의합니다. 이 플랫폼은 외과 의사의 디지털 확장 역할을

하여 외과용 현미경을 대체하고 무제한의 데이터를 통합 할 수 있는 증강현실

비전을 제공합니다."

영문

"BeyeOnics™, founded in 2018 within Elbit Systems (NASDAQ:ESLT), is a medical technology company developing surgeon-centered visualization solutions. Beyeonics is aiming to consolidate & Democratize Surgery, deliver a transformative technology - advancing the standard of care in connecting all of the capabilities of our technology and others. Use integrated augmented reality, tracking and image processing visualization platform to tell surgeons valuable information, to guide decisions and perform automatic tasks. The Beyeonics One™ Visualization Platform, our first system developed, redefines the standard for operating room (OR) visualization. The platform serves as a digital extension of the surgeon, providing augmented reality vision that replaces surgical microscopes and allows integration of unlimited amounts of data. The company has focused on Ophthalmology as entry market. Future expansion into Neurosurgery & Spine. Pipeline applications include minimally invasive surgery and surgical robotics"

제품소개

국문


Beyeonics One 은 전후방 부분 수술을 모두 최적화하도록 설계된 새로운

시각화 시스템입니다. 이 플랫폼은 외과 의사의 디지털 확장 기능으로 외과용

현미경을 대체하는 증강현실 시각화를 제공하는 동시에 무제한의 데이터

통합을 가능하게 합니다.

영문

Beyeonics One™ is a new visualization system designed to optimize both anterior and posterior segment surgery Beyeonics One is a disruptive ophthalmic visualization platform that integrates advanced technology in the form of enhanced visualization and customized stream of information into the surgical workflow. The platform serves as a digital extension of the surgeon, providing augmented reality visualization that replaces surgical microscopes, while enabling integration of unlimited amounts of data. It uses 3D visualization and digitalization capabilities such as image enhancement, and information connectivity which are fast becoming the new standard of care. The product includes unique features providing surgeons increased safety and performance.

http://www.beyeonics.com/


회사명 MobileODt (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.mobileodt.com

출품 품목 ©Algorithm / AI solution

회사소개

국문

MobileODT 는 인공지능을 통한 조기 암 발견 및 다양한 의료 목적을 위한 광학

진단 장치 및 소프트웨어 서비스를 개발합니다. 또한 장치를 작동하고 클라우드

기반 소프트웨어 플랫폼에 연결하는 직관적인 앱 기반 프로그램을 개발합니다.

영문

"MobileODT develops optical diagnostic devices and software services designed

for early cancer detection by AI (artificial intelligent) and a range of other

medical purposes. The company is creating advanced optical technology

components to turn smartphones into easy-to-use mobile point-of-care tools to

help detect cancer and capture a range of biomedical images for diagnostic and

other analytical purposes.

Mobile ODT also develops intuitive app-based programs to operate its devices

and connect them to a cloud-based software platform. The platform will enable

immediate remote consultation with experts for improved case management and

easy integration with a range of emerging electronic health record programs.

The company’s EVA COLPO is an FDA-cleared, internet-connected portable

colposcope that is as simple to use as a mobile phone. The device combines

advanced hardware with integrated software to serve a variety of clinical needs."

제품소개 국문


VisualCheck 는 임상의에게 자동화 된 임상 의사 결정 지원 도구를 제공하여

정상성 및 이상성 자궁 경관 소견을 평가할 수 있도록 합니다. 의료인의 임상적

판단을 대체하는 것은 아니지만, 매번 최고의 임상의 평가를 보장하는 추가 지원

도구입니다.

MobileODT 의 첨단시각평가 (EVA) 시스템은 AI 기반의 모바일 질경으로서, 신속한

자궁경부 검사를 수행하며, 이 검사를 완료 한 후 임상의는 포털의 이미지를

검토하고 VisualCheck 평가를 실행합니다."

http://www.mobileodt.com/

영문

"Introducing VisualCheck

VisualCheck provides clinicians with an automated clinical decision support tool

to assess for normal and abnormal cervical findings. Using an AI classifier,

VisualCheck predicts how a highly trained colposcopist might determine

suspected positive findings on the cervix and can alert healthcare providers

when they may want to reassess their first clinical impression.

While not a replacement for the clinical judgment of healthcare providers,

VisualCheck is an additional support tool to help ensure the best clinician

assessment every time. VisualCheck is intended for gynecologists and nurse

practitioners who have trained in VIA/colposcopy and know the art of

visualization of the cervix.

VisualCheck runs on the EVA System web portal using the images captured on

the EVA System colposcope. After completing a standard cervical cancer

examination with EVA System, the clinician will review the images on the portal

and run the VisualCheck assessment.

VisualCheck compares the images taken by the healthcare provider with a library

of images, annotated by international experts, to find how they would classify

similar images. Within seconds, the VisualCheck result is shown and recorded in

the EVA portal. If the clinician’s impression does not match that of the

VisualCheck result, the clinician will have the option to reassess their initial

finding."


회사명 Betalin Therapeutics (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.betalintherapeutics.com

출품 품목 Cell therapy

회사소개

국문 Betalin Therapeutics 는 당뇨병 치료를 위해 당뇨병 환자의 피부 내면에 이식 할

생물학적 micro-pancreas 를 만드는 세포 치료제 기업입니다.

영문 We are a cell therapy company creating a biological micro pancreas that will be

implanted under the skin of diabetic patients for treatment of diabetes.

제품소개

국문 출품품목-세포 치료법

영문 Product Category-Cell therapy

http://www.betalintherapeutics.com/


회사명 ProteKt Therapeutics Ltd. (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.protektx.com

출품 품목 Pharmaceutical

회사소개

국문

"ProteKt Therapeutics 는 신경 퇴행성 및 신경 염증성 질환 치료를 위한 kinase

PKR 의 잠재적인 선택적 억제제 개발하고 있습니다.

"

영문

ProteKt Therapeutics develops potent and selective inhibitors of the kinase PKR

for the treatment of neurodegenerative and neuroinflammatory diseases

ProteKt Therapeutics develops potent and selective inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases

제품소개

국문

"출품품목-제약

ProteKt 는 최첨단 IT 기술과 생화학적 접근 방식을 사용하여 PKR 의 새로운

강력하고 선택적 독점 소분자 억제제를 식별합니다. 이를 통하여 이러한 새로운

억제제 계열의 효능을 특성화하고 테스트하기 위한 일련의 분석법을 확립했습니다.

이러한 기술을 사용하여 PKR 억제제의 몇 가지 강력한 히트 제품군 확인하고,

알츠하이머와 관련된 모델에서 실험(in vitro activity)을 입증했으며 유망한 약물로

추가 개발하는 것을 목표로합니다."

영문

"Double-stranded RNA-activated protein kinase, or PKR, is a pro-apoptotic

kinase that controls the initial step of protein translation through the

phosphorylation of the eukaryotic initiation factor 2 alpha (eIF2α). This control of

protein translation machinery results in inhibition of protein synthesis in

response to cellular stress, a process known the Integrated Stress Response (ISR).

The reduction in protein translation is believed to result in memory consolidation

impairment, which may lead to cognitive disfunction.

PKR is involved in several cellular pathways including innate immunity and

defense against viruses. PKR can sequentially induced cell survival and death

pathways and also modulates the synthesis of pro-inflammatory factors via the

activation of the NF-kB pathway. PKR is also involved in the control of the

inflammasome and HMGB1 release. This kinase is highly expressed in

degenerative neurons in AD brains and can be activated in primary neuronal

cultures by Amyloid β. In addition, the levels of activated PKR are highly

increased in the cerebrospinal fluid (CSF) of patients suffering from Alzheimer's

Disease or Mild Cognitive Impairment and can correlate with the cognitive

http://www.protektx.com/

decline in AD patients. PKR is involved in neuroinflammation, apoptosis,

autophagy and Aβ-induced toxicity, which are all prominent features of AD, and

therefore is a good target for drug development for AD.

PKR inhibition is a novel mechanism for modulating multiple key processes in

AD and other neurodegenerative diseases. This multimodal approach may

overcome many of challenges that hindered the ability of other drug candidates

to successfully change the course of neurodegenerative diseases. This approach

is supported by a strong and growing body of preclinical and human evidences.

ProteKt uses state of the art computational and biochemical approaches to

identify novel potent and selective proprietary small molecules inhibitors of PKR.

We established set of assays to characterize and test the potency of these new

families of inhibitors. Using the techniques we established, we identified several

potent hit families of PKR inhibitors, demonstrated their in vitro activity in

models relevant for AD, and aims to further develop them into a promising

drug."


회사명 Stem-Cell Medicine (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.stemcell-medicine.com

출품 품목 Pharmaceuticals

회사소개

국문

Stem-Cell Medicone(SCM)은 세포 치료 팀의 경험과 CNS 질환 및 새로운 세포

기술을 이해하는 최근의 과학적 발전을 기반으로 10 년 전에 설립되었습니다.

Stem-Cell Medicine 은 예루살렘에 기반을두고 있으며 MS, 자폐증, 파킨슨 병, 신경

병성 통증, ALS, 이러한 질병에 대한 약물 전달 시스템, 세포 기반 치료 및 기존

약물의 조합을 포함한 신경 학적 징후에 초점을 두고 있습니다.

영문

Stem Cell Medicine (SCM) was founded 10 years ago based on the teams

experience in cell therapy and the recent scientific developments in

understanding CNS diseases and the new cell technologies. Stem Cell Medicine

has raised to-date $40 million, is based in Jerusalem and is focusing on

neurological indications, including MS, Autism, Parkinson’s, neuropathic pain,

ALS, drug delivery systems for these illnesses and combinations of cell based

treatments and conventional drugs.

제품소개

국문

출품품목-제약

현재 이스라엘의 연구 및 의료 센터로 부터 라이센스를 받은 5 개의 리딩 프로그램

포트폴리오를 개발 중입니다.

영문

We have built a portfolio of 5 leading programs which were developed internally

and licensed from research and clinical centers in Israel which we have been

scouting for the past 10 years:

1. Adipose-derived Mesenchymal Stem Cell (ADSCs) for SPMS and in

combination with long acting MS drugs

2. Exosomes for treating Autism

3. Exosomes as drug delivery systems

4. Genetically modified progenitor muscle cells for the treatment of

neuromuscular injuries

5. Anti-BMP for MS inflammations

We have built a GMP approved multidisciplinary R&D and clinical trials supply

facility in Jerusalem, recently received additional funding from the Israeli Ministry

of the Economy to build a gene therapy facility and are about to initiate the first

in-human studies.


회사명 VBL Therapeutics (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.vblrx.com

출품 품목 biopharmaceutical company

회사소개

국문

VBL Therapeutics 는 2000 년 설립된 나스닥 상장사로, 후기 단계의 임상 바이오

제약 회사입니다. 암 및 면역 / 염증 적응증에서 충족되지 않은 필요 영역을 위한

동급 최초 치료제의 발견, 개발 및 상업화에 중점을 둡니다.

영문

VBL Therapeutics is a publicly traded (NASDAQ: VBLT), late-stage clinical

biopharmaceutical company focused on the discovery, development and

commercialization of first-in-class treatments for areas of unmet need in cancer

and immune/inflammatory indications.

VBL has pioneered and is actively developing three novel platform technologies.

The Company’s most advanced program is the anti-cancer gene-therapy

program, in which VB-111 is the lead candidate. VB-111 is positioned to

potentially treat a wide range of solid tumors. VB-111 is conveniently

administered as an IV infusion once every 6-8 weeks. It has been observed to be

well-tolerated in >300 cancer patients. The mechanism of VB-111 combines

blockade of tumor vasculature with an anti-tumor immune response. This

mechanism may retain activity regardless of baseline tumor mutations or the

identity of the pro-angiogenic factors secreted by the tumor.

VB-111 has received orphan drug designation in both the United States and

Europe and was granted Fast Track designation by the FDA for prolongation of

survival in patients with glioblastoma that has recurred following treatment with

standard chemotherapy and radiation. VB-111 has also received an Orphan

Designation for the treatment of ovarian cancer by the European Medicines

Agency (EMA).

In December 2017, VBL Therapeutics has launched OVAL, a potential-

registration Phase 3 study of VB-111 in platinum resistant Ovarian Cancer in

collaboration with the GOG Foundation, Inc. In addition, VBL has developed two

innovative programs that are based on our novel biological findings related to

an exciting new highly specific protein called MOSPD2. Our finding unrevealed

the role of MOSPD2 in controlling directed cell movement of immune and tumor

cells. We are developing proprietary monoclonal antibodies targeting MOSPD2

for immune inflammatory diseases with proof-of-concept data in multiple

sclerosis and preliminary data in other indications. In a second program, we are

developing bi-specific antibodies that bring together tumor cells via MOSPD2

and T-cells via CD3, and thus recruits the immune system to fight tumor cells.

VBL has also developed a proprietary platform of investigational orally-available

anti-inflammatory small molecules, designated Lecinoxoids, for the treatment of

chronic immune-related indications.

Founded in 2000, VBL is based in Modiin, Israel.

제품소개

국문

출품품목-바이오 의약품

VBL Therapeutics 는 기능이 알려지지 않은 막 단백질인 MOSPD2 에 대한 연구를

통하여, 이 단백질이 세포 운동성 조절에서 중요한 역할을 하는 것으로 보이는

중요한 생물학적 발견을 하였습니다. 연구 데이터는 MOSPD2 가 종양 세포와 특정

면역 세포의 방향성 이동 또는 주화성(走化性)에 필요 요소임을 보여주고 있습니다.

VBL 의 생물학적 제제 VB-600 플랫폼은 종양학 및 염증성 적응증에 적용할 수 있는

MOSPD2 개발을 목표로 하고 있습니다. 다중 종양에서 발현이 유도되는 표적인

MOSPD2 를 기반으로 종양 세포 사멸을 목적으로 하는 이중 특이 항체를 개발하고

있습니다.

영문

MOSPD2 is a membrane protein whose function was unknown. We discovered

new biology findings in the regulation of cell motility, in which MOSPD2 seems

to be playing a key role. Our data indicate that MOSPD2 is required for

directional movement, or chemotaxis, of tumor cells and certain immune cells.

Our VB-600 platform of biologic agents is targeting MOSPD2 for oncology and

inflammatory indications.

We are developing bi-specific antibodies aimed to kill tumor cells, based on

MOSPD2 as a target whose expression is induced in multiple tumors.

MOSPD2 can be found in many types of solid tumors, and it seems to be highly

expressed on tumor cells when they start invading tissues or creating metastatic

lesions. This correlates with the role we identified for MOSPD2 as a key regulator

of cell motility in tumor cells. Our preliminary data indicate that knock-out of

MOSPD2 in tumor cells may reduce metastasis by 95% in some pre-clinical

settings.

In July 2018, we published a manuscript demonstrating, for the first time, that

MOSPD2 can play a major role in breast cancer cell migration and metastasis.

Histological analysis of human specimens shows that MOSPD2 levels were

correlated with the stage of tumor invasiveness, and were profoundly elevated in

invasive and metastatic breast cancer.

Based on these findings, our approach is to utilize MOSPD2 as a target for

attacking the tumor cells in the treatment of late-stage breast cancer and other

tumor types.


회사명 MICA AI Medical (이스라엘경제무역대표부)

국가 Israel

홈페이지 liorwayn.wixsite.com/micamedical


회사소개

국문

MICA(Mammography Image Comparison Analysis)는 유방암 방지 분야에

사용되는 의사 결정 정보 허브 및 의료 기록 플랫폼으로, 가슴 조직에 대한 변화를

자동으로 분석 및 확인하여 줍니다.

영문

MICA (Mammography Image Comparison Analysis) is Automated Comparison

alert platform of new and changed breast tissue - a decision support information

Hub and Medical Record platform for the Breast Cancer prevention arena.

MICA is based in Israel, with a goal to leverage a winning combination of the

“Startup Nation” with the “Global leader in Machine vision Tech”.

제품소개

국문

출품품목-알고리즘 / AI 솔루션

AI 와 기계 학습을 활용한 유방암의 조기 검진용 의사 결정 시스템 DENISE(Dense

Breast Innovative System)는 기존 MRI 및 CESM(Contrast-Enhanced Spectral

Mammography) 방식에 컴퓨터를 활용한 분석을 가능케 해줍니다. 세계적으로

인정받는 이스라엘 Sheba 병원의 Meirav Breast Center 와 CILAB 을 통하여

개발되었으며, 임상 170 케이스에서 90%의 정확도와 함께 불필요한 조직검사를

30% 가량 낮춰주였습니다. 미국, 유럽, 이스라엘에 특허가 등록되어 있습니다.

영문

MICA uses AI (Artificial Intelligence) and ML (Machine learning) to develop

decision-support system for the early detection of breast cancer.

DENISE (Dense Breast Innovative System)

40% to 50% of women below 50 years have dense breast, which materially

lowers mammogram accuracy.

Currently, women with dense breast are referred to alternative tests, such as

MRI, which is more expensive and less available. CESM (Contrast-Enhanced

Spectral Mammography) combines mammography + contrast agent injection

has been shown to be effective. In multiple studies, CESM equaled MRI in its

ability to detect breast cancer and was superior to the combination of standard

mammography and breast ultrasound; however, computer-assisted systems to

analyze such mammograms are still missing.

MICA's DENISE is an AI-based algorithm that provides decision-support to the

radiologist.

DENISE was developed at the SHEBA Hospital – one of the leading medical

centers worldwide, with the involvement of Meirav Breast Center and CILAB.

Clinical validations conducted at SHEBA with approx. 170 cases showed an

increase of mammography accuracy to 90%; and decreased unnecessary biopsies

by 30%.

It is covered by US Patent No. 10,499,866; and by corresponding patents in the

EU and Israel


회사명 SPACEPHARMA (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.space4p.com

출품 품목 SPACE AND LIFE SCIENCES RESEARCH AND PRODUCTION

회사소개

국문

2012 년 설립된 SpacePharma 는 미세유체공학기술일 기반으로 한 소형화

연구실을 만들었습니다. 이를 통하여, 포물선 비행에 대한 지상 실험 장치,

나노위성과 같은 다양한 플랫폼을 제공합니다. SpacePharma 는 연구실을 사용하는

연구자들이 결과를 확인하고, 그에 따라 실험 운용을 변경할 수 있도록 하는 우수한

소형화 연구실 운용 소프트웨어를 갖고 있습니다

영문

SpacePharma is a company which was established in April 2012 to create

miniaturized research laboratories, based on micro-/milli-fluidics technology, for

use in a variety of different platforms from on-ground simulators, through

parabolic flights, to Nano-satellites. SpacePharma has proprietary end-to-end

software for the operation and control of miniature laboratories that will send

results back to the scientist who is operating the experiment and allows them to

make changes to experiment operation based on those results.

제품소개

국문

출품품목-우주 및 생명과학 연구 및 생산

SPACEPHARMA 는 미세 중력 환경에서 유체 취급을 위한 맞춤명 규격 시스템을

갖추고 있습니다. SPACEPHARMA 는 SpacePharma 실험실을 위해 기계, 전자, 전기

광학, 통신뿐만 아니라 미세 유체 및 생명 공학 분야에서 고급 기술 개발을

수행합니다. SPACEPHARMA 는 또한 고객에게 몇 가지 유형의 미세 중력

시뮬레이터로 구성된 우주 비행 실패 위험을 완화하기위한 초기 환경 테스트를

제공합니다.

영문

SPACEPHARMA has a customizable off the shelf system for fluid handling in the

microgravity environment. SPACEPHARMA carries out advanced technology

development in mechanics, electronics, electro-optics, communications as well as

in microfluidics and biotechnology for the SpacePharma laboratory.

SPACEPHARMA also offers its customers initial environmental testing to mitigate

risks for failure in space flight which is composed of a few types of microgravity

simulators.


회사명 The National Institute for Biotechnology in the Negev (NIBN)

(이스라엘경제무역대표부)

국가 Israel

홈페이지 nibn.co.il

출품 품목 Research tool

회사소개

국문

NIBN - The National Institute for Biotechnology in the Negev 는 이스라엘

벤구리온 대학에 위치해 있는 독립적인 국립 생명 공학 연구 기관입니다. 명확한

생명 공학의 비전에 따라 학제 응용 연구를 실시하고 기초 연구와 응용적인 혁신

연구의 격차를 해소하고 새로운 아이디어의 상업화를 촉진시킵니다. NIBN 의

연구는 다양한 분야에 적용되며, 새로운 표적 식별 및 새로운 접근법 개발을

포함합니다. 암, 신경퇴행성 및 대사질환, 자가면역 및 염증성 질환, 감염성 질환 및

유전 질환을 위한 저분자, 단백질, 펩타이드 및 플랫폼 개발.

영문

The National Institute for Biotechnology in the Negev, LTD. (NIBN), a unique

research institute located within Ben-Gurion University of the Negev (BGU), is the

first self-organized, independent research entity established under the auspices

of a university in Israel. The NIBN is the home for accelerating BGU’s bio-applied

translational discovery and research and its mission is to conduct multi-

disciplinary applied research guided by a clear biotechnology vision, to bridge

the gap between basic and applied innovative research and facilitate the

commercialization of novel ideas and technologies developed by its

researchers.Research at the NIBN is applied to a variety of research fields and

includes identification of new targets and the development of novel approaches,

small molecules, proteins, peptides and platforms for the treatment of cancer,

neurodegenerative and metabolic diseases, autoimmune and inflammatory

diseases, infectious diseases and human genetic disorders.Partnerships with

NIBN: “Tailor-made” partnership opportunity for each developed IP.Partnerships

options: • Licensing out the IP, either to be integrated into Bio pharma

company’s pipeline or to establish a new company for the development of the

licensed IP or co-develop with third party.• Joint development with a partner to

create a new joint IP.• Create research collaborations; maximize the potential of

exchanging ideas and technologies.

제품소개

국문

출품품목-연구도구완전한 기능을 유지하며 치료 단백질의 탈면역화를 위한 계산적

및 실험적 접근 방식을 결합하는 플랫폼 기술입니다. 이 플랫폼은 치료 단백질에서

CD4 T cell epitopes 를 신속하게 식별하고 단백질 공학 기술을 사용하여 제거할 수

있습니다.

영문

A platform technology that combines computational and experimental

approaches for the de-immunization of therapeutic proteins while maintaining

full function. The platform enables rapid identification of CD4+ T cells epitopes

in therapeutic proteins, and their elimination using protein engineering

technologies.De-Immunization Process includes four steps:• Epitopes Prediction

Comprehensive analysis of CD 4 epitope hotspots in the target sequence using

state of the art computational prediction tools• Experimental Validation

Verification of predicted epitopes using functional T cell assays i. e. ELISpot and

ICS• Epitopes Elimination using protein engineering Rational application to smart

libraries for yeast surface display high throughput screening to obtain variants

with reduced immunogenicity maintaining protein functionality and stability•

Experimental Assessment The reduced immunogenicity of the selected variants is

tested using functional T cell assaysProof of concept De-immunization was

demonstrated in Humira and CTLA 4.Opportunity: De immunization is a platform

technology which can be tailored and applied to many therapeutic proteins to

overcome ADA challenge.Examples: • The technology can be implemented as an

integral part in early drug development stages.• The technology can be utilized

for enhanced immunogenicity in vaccine development (both CD4 and CD8)•

Depletion of B cell epitopesThe technology is open for co-development and out-

licensing


회사명 HT BioImaging Ltd (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.htbioimaging.com


회사소개

국문

HT BioImaging 은 혁신적인 의료 영상 스타트업으로, 암을 조기에 발견하고

분류하는 것을 목표로 합니다.

AI, 신호분석 및 검퓨터 비전 전문가, 열전달 및 열역학 수석연구원, 종양학자,

방사선학자 등 뛰어난 인력이 팀을 이루고 있습니다.

영문

HT BioImaging is a revolutionary patented medical imaging Startup. Our goal is

to detect and classify cancer early on the spot. Our exceptional team includes AI,

signal analysis and computer vision experts, heat transfer & thermodynamics top

researchers, oncologists, radiologists, and one successful serial entrepreneur.

제품소개

국문


HT BioImaging 은 고유한 열 흐름 특성을 활용하여 암세포를 인식 할 수 있는

획기적인 특허 의료 영상 기술을 개발했습니다. 열 확산을 사용하여 조직의 열

분산을 기록하여 조직에서 관찰 된 불연속성을 암으로 식별 할 수 있으며, 100 명의

환자를 대상으로 한 임상시험에서 96%의 정확도를 확인할 수 있었습니다.

HT BioImaging 은 이 기술을 기반으로 한 HTPScan 스캐너를 통해 구강암,

자궁경부암 및 피부암을 조기에 발견하고 1 차진료소 또는 외과의가 수술실에서

암을 제거하도록 도와줍니다.

영문

HT BioImaging has developed a breakthrough, patented, medical imaging

technology able to recognise cancerous cells by exploiting their unique heat-

flow properties, using thermal diffusion to record heat dissipation in the tissue

enabling it to identify the observed discontinuity in the tissue as cancerous, with

an accuracy of 96% as approved in 100 patients in clinical trials. Based on this

technology, HTB is introducing a hand-held Scanner for the point of care and

community physicians - HTPScan – for the early detection of oral, cervical and

skin cancers, easily performed at the community and primary care offices, as well

as to help surgeons to remove cancer at the operation rooms.


회사명 Beaconcure (이스라엘경제무역대표부)

국가 Israel

홈페이지 beaconcure.com


회사소개

국문

BeaconCure 는 규제 제출의 품질과 주기 시간을 개선하기 위해 맞춤화 된

클라우드 기반 & AI 기반 임상 데이터 분석 플랫폼을 개발했습니다.

인공 지능을 활용하여 의약품 개발 및 규제 승인 과제를 개선합니다.

영문

BeaconCure has developed a cloud-based, AI-driven clinical data analytics

platform tailored to improve the quality and cycle time of regulatory

submissions. The company leverages artificial intelligence to improve mission-

critical business challenges in drug development and regulatory approvals.

제품소개

국문 출품품목-알고리즘 / AI 솔루션

AI 를 포함한 신약 개발 및 정밀의학 신약을 개발합니다.

영문

Verify by BeaconCure is an automated analytics & validation software tool driven

by AI. Developed in collaboration with Pfizer Inc. it supports and empowers

regulatory submissions.


회사명 FutuRx (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.futurx.co.il

출품 품목 Biotech and Pharma

회사소개

국문

FutuRx 는 Takeda Ventures, Johnson&Johnson (JJDC), Bayer 와 Orbimed Israel

Partners 가 설립한 이스라엘 바이오 벤처 기업입니다. FutuRx 는 이스라엘

생명공학 생태계와 이스라엘 및 전 세계 주요 연구 기관 정보를 활용하여 매우

혁신적인 기술을 식별 및 개발합니다.

아울러, Takeda, Johnson&Johnson, Bayer 및 OrbiMed 의 전문가들은 프로젝트

선정 과정 및 인큐베이션 기간 동안 깊이 관여하여 혁신적인 연구를 효율적으로

제품화합니다. 현재까지 20 개의 기업이 선정되었습니다.

영문

FutuRx is a partnership of four leading global healthcare players ? Takeda

(Takeda Ventures Inc.), Johnson & Johnson (JJDC), Bayer (LEAPS by Bayer) and

OrbiMed Israel Partners. By combining the expertise of its management and the

capabilities of its founders, FutuRx provides a unique model for the

transformation of breakthrough discoveries into novel medicines.

FutuRx leverages its access to the Israeli biotech ecosystem, and to leading

research institutes in Israel and worldwide, to identify and develop highly

innovative technologies. Experts at Takeda, J&J, Bayer and OrbiMed are deeply

involved in the project selection process and during the incubation period of

each company. The result is an efficient translation of innovative research to

clinically meaningful products. 20 companies have been incepted to date and

significant follow- n rounds have been raised by the graduates.

제품소개

국문 출품품목-생명공학 및 제약

AI 를 포함한 신약 개발 및 정밀의학 신약을 개발합니다.

영문 Product Category-Biotech and Pharma


회사명 Matricelf (이스라엘경제무역대표부)

국가 Israel

홈페이지 www.matricelf.com

출품 품목 3D printing of tissues and organs

회사소개

국문

Matricelf 는 이스라엘 텔아비브에 위치한 조직 공학 분야의 기업으로 조직 및 장기

이식의 거부 반응을 크게 줄이는 3D 프린팅 플랫폼을 개발합니다. Dvir 교수

연구진은 2019 년 역사상 처음으로 3D 프린터를 이용해 입체적 인공 심장을

만드는데 성공하였고, 급성심근경색, 파킨슨병, 황반변성 등과 같은 여러 질병을

대상으로 성공적인 전임상연구를 완료했습니다.

영문

Matricelf (www.matricelf.com) is a biotechnology company in the field of tissue

engineering located in Tel Aviv, Israel.

The company develops a platform for autologous (personal) 3D printing of

tissues and organs that significantly reducing the risk of implant rejection.

In April 2019, the technology enabled researchers in Prof. Dvir's lab to print, for

the first time in human history, a three-dimensional human heart from human

tissue.

The company completed successful pre-clinical studies in a number of medical

conditions such as acute Myocardial Infarction, Parkinson's Disease, Age related

Macular Degeneration and more.

제품소개

국문

출품품목- 인체 조직 및 장기의 3D 프린팅

첫 임상 적용은 외상성 척수 손상으로 고통받는 환자를 위한 척수 이식에 중점을

두고, 환자의 운동 기능을 회복하고 일상 생활을 할 수 있도록 돕습니다.

영문

For its first clinical application, Matricelf focuses on spinal cord implants for

patients suffering from traumatic Spinal Cord Injuries.

The company hopes that with its technology, these patients will be able to

restore motor function and assist them in daily activities and integrate back into

the community.


회사명 PT. Phapros, Tbk

국가 Indonesia

홈페이지 www.phapros.co.id

출품 품목 Generic Medicines, herbals, etc.

Pharmaceutical Finished products, Herbal finished products, Supplement

회사소개

국문

영문

Phapros, a leading pharmaceutical finished products manufacturer in Indonesia,

established in 1954, and has been certified by cGMP, ISO 9001, ISO 14001, ISO

18001, ISO 17025. We produce ethical medicine, Over the counter medicine,

herbal medicine and health supplement. We are now also expanding our medical

devices sector. Now Phapros is expanding its export market.We have exported

our products to Cambodia, and register several products to Vietnam, Philippines,

Peru and Nigeria. We want to add more countries as our export target. Now

we’re focusing on Asia, Africa and Middle East Region.

Export Markets: Asean, Africa, South America

제품소개

국문

영문

Pharmaceutical Finished products, Herbal finished products, Supplement,

Branded-Generic Medicines


회사명 Kalbe International

국가 Indonesia

홈페이지 kalbeinternational.com

출품 품목 Pharmaceutical products such as Woods’ cough syrup, Mixagrip cold & flu,

Procold cold & flu, Komix cough syrup, etc.

회사소개

국문

영문

Kalbe International is a subsidiary of Kalbe Group Indonesia and fully in-charge

for the international market. Kalbe is an Indonesian Pharmaceutical Company

who is currently focused in 4 lines of business i.e. Ethical, OTC, Nutrition and

Consumer. Kalbe is currently the biggest publicly-listed pharmaceutical company

in Southeast Asia, commanding a sales turnover USD 1.6 billion by end of year

2019.

Export Markets: ASEAN countries, Mongolia, Nigeria, South Africa, Ghana,

Burkina Faso

Details about Interest: Export

Name/Type of Korean Companies Hope to Meet: Pharmaceutical & FMCG

distributors

제품소개

국문

영문 Pharmaceutical products such as Woods’ cough syrup, Mixagrip cold & flu,

Procold cold & flu, Komix cough syrup, etc.


회사명 PT Kimia Farma Tbk

국가 Indonesia

홈페이지 www.kimiafarma.co.id

출품 품목 Drug, Herbal, Cosmetic, Oil

회사소개

국문

영문

PT Kimia Farma Tbk. is Indonesia pharmaceutical stated-owned enterprise that

provides chemical and pharmaceutical products in diverse categories, such as

prescription drug, over-the-counter drug, natural oil, cosmetics,

radiopharmaceuticalkit,and test kit. Asan integrated healthcare company,KF has

its own Active Pharmaceutical Ingredients (API) Manufacture and currently has 50

Distributors, 1138 Pharmacies, 530 Clinics, 10 Optics, and 55 Diagnostic

Laboratories covers in more than 170cities in the country.

Export Markets: Asia, Europe, America, Africa

Specific Items Want to Export/Import: Export : Coconut Oil, Peanut Oil,

Indonesian Herbal medicine, Import : Biosimilar, Oncology, Respiratory, Anti

Retroviral, Narcotic, Medicine, Cosmetic

제품소개

국문

영문

Prescription Drug, Over-The-Counter Drug, Herbal, Cosmetic, Oil, Raw Material,

Radiopharmaceutical Kit, and Test Kit


회사명 PT Sanbe Farma

국가 Indonesia

홈페이지 www.sanbe-farma.com

출품 품목 Therapeutic

회사소개

국문

영문

PT Sanbe Farma, is one of the largest Pharmaceutical Manufacturers in Indonesia

catering to Human Healthcare products by active promotion / prescription

generation of ethical products (with various kinds of dosage forms such as

capsules, tablets (plain, film coated and sugar coated), drops, syrups, dry syrups,

powder / effervescent powder, creams, ointments, sterile eye drops, sterile

injection (dry powder / solutions), suppositories) and Animal Health formulations,

including Vaccines, promoted and provided to Farmers at affordable prices.As

per the latest Indonesia Pharmaceutical Audit, published by IQVIA, PT SANBE

FARMA ,we are among the larger player for the Sales for Prescription Drugs

from among 250+ Pharmaceutical Manufacturers including the Multinationals.

We ranked among top players as per the latest and recent years IQVIA (JV of

Quintiles and IMS ) data in Indonesia with audited market share of around 7% in

the territory for Ethically prescribed medicines marketing and sales.

PT SANBE FARMA has dedicated facilities for production of Penicillin’s,

Cephalosporin’s, Carbapenems, “State of the Art” production facilities for Large

Volume Parenteral (LVP / Infusion) using non-PVC flexible Poly propylene

softbag from Cryovac, USA, Small Volume Parenteral (SVP), Eye Preparations, Fat

Emulsions, Today, We are proud to say that, PT SANBE FARMA is the First

Pharmaceutical Manufacturin g Company in Indonesia Established the dedicated

manufacturing facility for Oncology products (Lyophilized and Liquid injectable)

and Biologicals which includes Insulins, MABs & Bio Similar products in

compliance with ICH guidelines and regulatory standards. In the path to succeed

and lead, PT SANBE FARMA is setting up, the new Soft Gelatin Manufacturing

Facility will be operational in the days to come. Very recently in June 2017, our

penicillin Plant has been approved by WHO GMP and one of our product

oxytocin Injection is the first generic to be prequalified by WHO which is from

our another facility called Sterile Preparation plant. For both these we are the

first and only in Indonesia.Our Corporate Group consist of 11 Pharmaceutical

Manufacturing Facilities / Animal Vaccine Facilities spread across two different

industrial sites near Bandung. As a Group of companies, we have another

company called PT Caprifarmindo which is also a Pharmaceutical manufacturer

for oral dosage forms of medicines for Human and veterinary health, PT Bina

SanPrima, a Large Distribution Company, Group of Hotels and Corporate

Hospitals.

Export Markets: Row ( SEA.Middle East,Aftrica,Latin America, CIS, APAC, etc)

제품소개

국문

영문 Most of the therapeutic ranges


회사명 LSI Medicine Corporation

국가 Japan

홈페이지 www.medicine.co.jp/english/index.html

출품 품목

회사소개

국문

영문

“Providing Healthcare Solution Domestically and Abroad By Combining Medical

with Science, and Supporting Your Health by Constant Efforts and Progress”

LSI Medience Corp. (hereinafter LSI Medience) has been developing “Clinical

Laboratory Business”, “In Vitro Diagnostics Business” and “Drug Development

Support Service Business” by putting its testing/analytical techniques as a core

competence in the healthcare field, and expanding a variety of service, service

provision area, and related products under management vision “Good Health

Creator, MEDical+sciENCE ? for healthy and secure society creation”. In August,

2019, LSI Medience became a group company of PHC Holdings Corporation

which is a global healthcare company developing its operation in 125 countries

worldwide. LSI Medience will provide unprecedented new value by combining

the high level of product/service development capability, production

technological capability, and overseas customer bases of PHC group with the

techniques, knowledge and customer bases which LSI Medience has cultivated

for a long time.

제품소개

국문

영문

LSI Medience provides consistent support services for drug development from

the stage of non-clinical studies to clinical studies”

(1) In the drug development support services, LSI Medience offers its support

services such as performing of assays, tests, and analyses for pharmaceutical

companies, public institutions, and general business entities. In the development

of drugs, LSI Medience provides consistent services that cover exploratory

studies, non-clinical studies, clinical studies (bioanalysis service and central

laboratory service), and post-marketing studies.

(2) At the Clinical Development Service Center of LSI Medience, by utilizing its

advanced testing/analysis technology accumulated as comprehensive clinical

testing center, and its high-tech equipment and facilities, LSI Medience has been

promoting to support pharmaceutical companies in their new drug development

(3) LSI Medience provides both “bioanalytical services” and “central laboratory

services” to support clients' drug development process. LSI Medience has

experienced a lot of the studies entrusted for each phase in the drug

development process and in a wide range of therapeutic areas, for which LSI

Medience has earned the trust of many customers.

(4) LSI Medience has been implementing main programs including drug

analyses, biomarker analyses and bio-banking services at its GLP compliant

bioanalytical lab. Furthermore, LSI Medience’s main central laboratory covers a

wide range of tests from general safety tests to specialized tests. LSI Medience’s

main central laboratory maintains ISO15189, as global standard for clinical

laboratory, and College of American Pathologists (CAP) accreditation.

(5) LSI Medience provides its high quality data required for applications in Korea

and Japan as comprehensive services.


회사명 Thornhill Medical

국가 Canada

홈페이지 thornhillmedical.com

출품 품목 의료 기기 / 의료 / 군사 / 민방위 기술

회사소개

국문

Thornhill Medical 은 군대, 응급, 모바일 및 원격/엄격 의료 서비스 분야에서

사용되는 새롭고 가치 있는 헬스케어 기술 시스템과 기기를 설계, 제조 및 공급하는

캐나다 회사입니다. Thornhill Medical 은 상용화된 여러 제품과 조사 기구를

보유하고 있으며 이는 현재 4 개 대륙, 19 개 이상의 국가와 50 개 이상의

연구기관에서 사용되고 있습니다.

영문

Thornhill Medical is a Canadian based designer, manufacturer and supplier of

novel and valuable healthcare technology systems and devices used in military,

emergency, mobile and remote/ austere health delivery sectors. Thornhill

Medical has a suite of commercialized products, and one investigational tool,

that are currently in use on 4 continents, by 19+ countries, and at 50+ research

institutes.

제품소개

국문

영문 Medical Device/ Healthcare/ Military/ Civil Defense Technology


회사명 Qubit Systems

국가 Canada

홈페이지 qubitsystems.com

출품 품목 연구 및 교육용 과학 장비

회사소개

국문

Qubit Systems 는 생명과학 분야의 연구와 교육을 위한 과학 장비를 설계하고

제작합니다. 당사의 분석기와 소프트웨어는 식물, 동물, 곤충, 어류, 박테리아 조류,

사람 등 여러 유기체의 생리학적 과정을 측정합니다. 특별히 최신 제품은 VO2,

VCO2 및 관련 피트니스 매개 변수를 모니터하기 위해 호흡 시의 산소와

이산화탄소를 추적 관찰함으로써 인간의 심장혈관 적합도를 측정하고 있습니다.

현재 유관 학계, 산업계, 피트니스/스포츠 업계의 연구 시장에 제품을 판매하기

위해 한국과 동남아시아 내 유통사를 찾고 있으며 이 분야의 전문성과 네트워크를

갖춘 곳 이상적인 파트너를 만나기 희망하고 있습니다.

영문

Qubit Systems Inc. designs and builds scientific equipment for research and

teaching in the biological sciences. Our analysers and software measure

physiological processes in a range of organisms including plants, animals,

insects, fish, bacteria algae and humans. Our latest products focus of measuring

human cardiovascular fitness by monitoring breath oxygen and carbon dioxide

levels to monitor VO2, VCO2 and related fitness parameters. We are seeking

distributors in Korea and SE Asia to sell our products into research markets

(academic, industrial and fitness/sports related). The ideal partner will have

expertise and a network of contacts in these fields.

제품소개

국문

영문

Scientific equipment for research and teaching. Focus on cardiopulmonary

exercise testing (CPX)


회사명 Triple Hair

국가 Canada

홈페이지 triplehair.ca

출품 품목 탈모 치료제

회사소개

국문

Triple Hair 는 혁신적 탈모 치료법을 개발 중인 임상 단계의 바이오테크

회사입니다. 의학 용어로 알로페시아(alopecia)라 불리는 탈모는 전 세계 인구의 약

20%가 겪고 있는 질환입니다.

영문

Triple Hair is a clinical stage biotechnology company developing innovative

treatments for hair loss, clinically referred to as alopecia, which impacts

approximately 20% of the human population.

제품소개

국문

영문 Hair loss (alopecia)


회사명 Primary Peptides

국가 Canada

홈페이지 primarypeptides.com

출품 품목 뇌졸중, 심장 마비, 신경 퇴행, 암 관련 펩타이드 치료제

회사소개

국문

Primary Peptides 는 캐나다 밴쿠버에 기반을 둔 임상 단계의 바이오테크

회사입니다. 당사는 두 가지 플랫폼 기술을 이용해 신규 펩타이드 치료법을

개발하는 중인데, 하나는 특정 단백질 간 상호 작용을 파악, 표적하고 분열 시키는

펩타이드 어레이, 나머지 하나는 안티센스와 여러 지표 내의 siRNA 기술 플랫폼을

보다 구체적이고 시간적으로 정밀하게 대체할 수 있는 펩타이드 중재 단백질

녹다운 기술입니다. Primary Peptides 는 지금까지 4 곳의 제약회사와 파트너십을

체결했습니다.

영문

Primary Peptides Inc is a clinical-stage biotech company based in Vancouver,

Canada. We are developing novel peptide therapeutics using two platform

technologies: 1) peptide array for identifying, targeting, and disrupting specific

protein-protein interactions; 2) peptide-mediated protein knockdown technology

that can replace antisense and siRNA technology platforms in many indications

with greater specificity and greater temporal precision. We have signed 4

pharma partnerships so far.

제품소개

국문

영문 Peptide therapeutics for stroke, heart attack, neurodegeneration, cancer


회사명 Lumira Ventures

국가 Canada

홈페이지 lumiraventures.com

출품 품목 생명 공학 및 의료 기기 VC

회사소개

국문

Lumira Ventures 는 캐나다에서 가장 활발한 선두 헬스케어 벤처캐피털

회사입니다. Lumira Ventures 는 혁신적인 치료 및 의료 기술을 개발하는 최우수

북미 기업에 투자하고 있으며, 이를 통해 환자의 건강을 크게 개선하고 의료

서비스에 지불하는 전체 비용을 감소시킬 수 있도록 노력하고 있습니다. 기업 설립

이후 지금까지 Lumira Ventures 의 포트폴리오 기업은 50 개 이상의 치료법을

시장에 출시했으며, 전 세계 10 억명 이상의 환자들에게 영향을 주었고 , 누적 매출

기준 650 억 달러 이상을 기록했습니다.

영문

Lumira Ventures is Canada’s leading and most active healthcare venture capital

firm. Lumira invests in best-in-class North American companies developing

innovative therapeutics and medical technologies whose products offer

transformative improvements to patient health outcomes and provide

meaningful reductions to the overall cost of healthcare delivery. Since inception,

Lumira’s portfolio companies have brought 50+ new therapies to market,

impacting the lives of 1+ billion patients globally, generating $65+ billion in

cumulative revenue.

제품소개

국문

영문 Biotechnology and Medical Device


회사명 AmorChem Ventures

국가 Canada

홈페이지 amorchem.com

출품 품목 VC 펀드 / 시드 파이낸싱 / 바이오 테크 기업 창출

회사소개

국문

몬트리올 소재, 초기 단계의 선두 벤처캐피털인 AmorChem 은 학술 연구를 통해

차세대 바이오테크 회사를 창출하는 데 집중하고 있습니다. 2011 년 자본금

41.25 백만 달러로 시작한 AmorChem I Fund 는 24 개 대학 기술 포트폴리오를

구성했으며, 3 개의 제약 프로젝트가 엑시트(exit)하고 6 개의 바이오테크 스핀오프

기업을 키워내는 성과가 있었습니다. 이런 시드펀드모델 (seed fund model)의

장점과 주요 역할은 퀘벡 주의 투자 시스템에서도 보여지고 있는데, 2017 년 9 월에

출시된 AmorChem II Fund 는 현재 53.7 백만 달러에 이르고 있으며 온타리오

주에서 활동을 넓혀 나가고 있습니다.

영문

Located in Montreal, AmorChemis a leading early-stage venture capital fund

focused on creating the next generation of biotech companies from academic

research. Launched in 2011 with $41.25M in capital, the AmorChem I Fund has

built a portfolio of 24 university technologies resulting in three successfully

transacted pharma exits and six biotech spin off companies. The attractiveness of

this seed fund model and the central role it plays in the investment ecosystem in

Quebec were highlighted in September 2017 with the launch of the AmorChem

II Fund, which currently totals $53.7M with expanded activity in the province of

Ontario.

제품소개

국문

영문 VC fund/seed financing/biotech company creation


회사명 PharmEng Technology

국가 캐나다

홈페이지 www.pharmeng.com

출품 품목 제약회사, 바이오의약품회사, 메디컬장비회사에 cGMP 와 EU GMP 관련 컨설팅

제공

회사소개

국문

PharmEng Technoloy 는 1997 년 캐나다 토론토에서 창립되어져서 미국, 유럽,

아시아 전역에 지사와 고객사를 보유하고 있는 글로벌 제약 토털 컨설팅

회사입니다. FDA 와 EU GMP 획득을 위한 Commissioning & Qualification,

Validation, Engineering, GMP/ Compliance, Toxicology, Regulatory Affairs, QC

/Microbiology ,Mock Inspection, Documentation (모든 문서 작성 및 리뷰),

Training 을 도와드리고 있습니다. 한국과의 다수 메이져 프로젝트 경험을 보유하고

있습니다.

영문

제품소개

국문

영문


회사명 Innomar Strategies

국가 캐나다

홈페이지 www. innomar-strategies.com

출품 품목 제약 / 의료 서비스 및 컨설팅

회사소개

국문

Innomar Strategies 는 AmerisourceBergen 에 소속되어 있는 회사로, 캐나다 특수

바이오의약품 시장 내 환자지원 분야를 선두하고 있습니다. 제품 접근성 개선,

공급망 효율성 증가, 환자 케어 강화를 위해 엔드투엔드(end-to-end) 상용화

솔루션을 제공합니다. 특화 분야로는 전략 컨설팅, 환자지원 프로그램, 간호, 임상

서비스, 특수 약제 및 물류 등이 있습니다. Innomar Strategies 는 환자들이 지속적

및 안정적으로 특수 약물에 접근할 수 있도록 제조업체, 헬스케어 업체, 제약 및

지불자(Payer) 와 긴밀히 협력하고 있습니다. Innomar Strategies 는 환자들이 최고

수준의 환자 케어를 받을 수 있도록 통합적으로 접근하고 노력하고 있으며, 이를

통해 환자들이 최적의 치료 결과를 얻을 수 있도록 지원합니다.

영문

Innomar Strategies, a part of AmerisourceBergen, is the leading patient support

provider in the Canadian specialty biopharmaceutical market. We deliver end-to-

end commercialization solutions to improve product access, increase supply

chain efficiency and enhance patient care. Strategic consulting, patient support

programs, nursing, and clinical services, and specialty pharmacy and logistics are

just a few of our key areas of specialization. We partner closely with

manufacturers, healthcare providers, pharmacies and payers to ensure patients

have consistent and reliable access to specialty medication. With our integrated

approach and commitment to best-in-class care, Innomar Strategies helps

navigate the patient journey to optimize health outcomes.

제품소개 국문

영문

Pharmaceuticals/Healthcare, Services and Consulting


회사명 Rostrum Medical Innovations

국가 캐나다

홈페이지 www. rostrummedical.com

출품 품목 심폐 모니터링 관련 의료 기기

회사소개

국문

Rostrum 은 환자 케어에 있어 발생하는 문제들을 해결하는 솔루션을 개발 및

상용화하고 있습니다. Rostrum 에는 여러 분야에 걸쳐 관리, 사업 개발, 임상 경험을

가진 팀이 있으며 Rostrum 의 대표들은 경영, 임상의학, 디자인 및 개발, 글로벌

마케팅 및 사업 경험에 대한 전문지식을 제공합니다.

영문

Rostrum develops and commercializes unique solutions for patient care. Rostrum

is managed by a team with extensive management, business development and

clinical experience. Its directors offer expertise in executive management, clinical

medicine, design and development and extensive global marketing and business

experience.

제품소개

국문

영문 Medical device for lung


회사명 Ovensa

국가 캐나다

홈페이지 www.ovensa.com

출품 품목 생명공학

회사소개

국문

전 임상 단계 기업인 Ovensa 는 종양 미세 환경에서 갈렉틴-1 의 과발현을

억제하는 siRNA 약물 후보를 개발하여 면역-종양 체크포인트 억제제 및 기타 암

치료제의 치료 효과 개선하고자 합니다.

Ovensa 는 자사의 비-바이러스 성 및 비-지질성 TRIOZAN ™ 약물전달 플랫폼을

활용하여 정밀·복합제 개발을 위해 제약사와 협력하고 있습니다.

현재는 siRNA 약물 후보를 임상에 적용하기 위해 1 천 5 백만 US 달러 규모의

시리즈 A 를 모집하고 있습니다.

영문

Ovensa is a Canadian preclinical stage company developing a siRNA drug

candidate silencing the overexpression of galectin-1 in the tumor

microenvironment to improve therapeutic outcomes of immuno-oncology

checkpoint inhibitors and other cancer drugs.

Ovensa works with pharmaceutical companies to develop precision and

combination medicines using its non-viral and non-lipidic TRIOZAN™ drug

delivery platform.

The company is currently raising a 15MM USD Series A to advance its siRNA into

the clinic.

제품소개

국문

영문

TRIOZAN Drug Delivery Platform that is non-lipidic and non-viral. Delivering to

targeted organs, cells and to the brain. Suitable for all routes of administration.

siRNA/Gal-1 (targeting Galectin-1) in combination with checkpoint inhibitors to

boost their efficacy and reduce cancer resistance.


회사명 Immune Biosolutions

국가 캐나다

홈페이지 www.immunebiosolutions.com

출품 품목 Human Therapeutics

회사소개

국문

Immune Biosolutions 는 인간화된 닭 항체의 발견, 설계 및 개발을 통해 효과는

있지만 활용되지 않은 치료적 잠재력이 있는 단백질을 표적으로 하는 바이오테크

회사입니다. 생물의약품이 생명을 변화시키고 살릴 수 있다고 믿는 Immune

Biosolutions 는 기술 플랫폼을 활용하여 닭의 면역 체계를 철저히 파고 들어

차세대 면역치료 개발과 설계에 힘쓰고 있습니다. 당사는 보다 신속하고

효율적으로 목표를 달성하기 위해 각종 전문 지식을 결합시킴으로써 다른 회사에서

실패했거나 시도조차 하지 못한 몇몇 치료법 영역 내의 (학계에서 대형 제약회사에

이르는) 파트너십을 통해 안전하고 근접성 높은 인간화된 항체를 만들고 있습니다.

영문

Immune Biosolutions is a biotech company focused on the discovery,

engineering and the development of humanized chicken antibodies targeting

difficult proteins with a validated and unexploited therapeutic potential. At

Immune Bio, we strongly believe that biologics can transform and save lives.

Leveraging our technology platforms, we hack the immune system of chickens to

discover and engineer the next generation of immunotherapies. We create safe

and high affinity humanized antibodies in several therapeutic areas in

partnerships (academia to big pharma) by combining expertise to achieve our

goals faster and efficiently, where others have failed or never dared to explore.

제품소개

국문

영문


회사명 Feldan

국가 캐나다

홈페이지 www.feldan.com

출품 품목 생명공학, 펩타이드 기반 세포 내 전달 기술

회사소개

국문

Feldan Therapeutics 는 차세대 치료 화합물의 세포 간 전달에 기반을 둔 치료법을

개발하고 있습니다. 당사가 설계한 Feldan Shuttle 은 펩타이드에 기반한 독특한

기술로서, 펩타이드와 단백질을 안전하고 효율적으로 세포 내에 전달시켜 차세대

치료 화합물의 치료 표적이 될 수 있는 세포 간 경로에 접근하는 것을 돕습니다.

영문

Feldan Therapeutics is developing treatments based on the intracellular delivery

of next-generation therapeutic compounds. The company has designed the

Feldan Shuttle, a unique peptide-based technology that allows safe and efficient

delivery of peptides and proteins into cells, giving these highly specific

compounds access to intracellular pathways that can be targeted for therapeutic

interventions.

제품소개

국문

영문 Peptide-based intracellular Delivery Technology / Biotechnology


회사명 BioMedica Diagnostics

국가 캐나다

홈페이지 www.biomedicadiagnostics.com

출품 품목 혈전증 및 지혈 관련 기술

회사소개

국문

BioMedica 는 혈전증 및 지혈 관련 혁신 기술을 보유한 회사입니다. BioMedica 는

국제적인 기술 개발 기업 및 헬스케어 이해관계자들과 협력하여 맞춤형 시약 및

진단 솔루션을 개발하고 생산합니다. BioMedica 는 비용을 절감하고 모든

이해관계자의 리스크를 줄이기 위해 매진하여 연구, 교육 및 시험관 진단에 필요한

도구를 개발합니다.

영문

BioMedica is your partner with core competencies in thrombosis, haemostasis

and innovative technologies. We collaborate internationally with technology

development companies and healthcare stakeholders to develop and

manufacture customized reagents and diagnostic solutions. Working hard to

lower costs and reduce and mitigate risks to all stakeholders, BioMedica

develops the tools needed for research, education and In-Vitro Diagnostics.

제품소개

국문

영문 Coagulation, Haemostasis, Thrombosis


회사명 Angiochem

국가 캐나다

홈페이지 www.angiochem.com

출품 품목 생명공학, Drug Peptide Conjugates

회사소개

국문

Angiochem 은 새롭고 혁신적인 펩타이드약물접합체를 발견하고 개발하는 임상

단계의 바이오테크 회사입니다. 이 접합체는 신경 질환을 치료하기 위해 혈액-뇌

장벽을 교차하는 LRP-1 중재 경로를 활용합니다. Angiochem 의 선도 화합물인

ANG1005 는 내년 초에 재발성 뇌전이연수막암종증(BCBMLC) 유방암 환자를

대상으로 3 상 임상 시험을 실시할 예정입니다.

영문

Angiochem is a clinical-stage biotechnology company discovering and

developing new breakthrough peptide drug conjugates that leverage the LRP-1

mediated pathway to cross the blood brain barrier (BBB) to treat neurological

diseases. Our lead compound, ANG1005 will be going into a Ph III trial in Breast

Cancer patients with recurrent Brain Metastases and Leptomeningeal

Carcinomatosis (BCBMLC) early next year

제품소개

국문

영문 Biotechnology, Drug Peptide Conjugates


회사명 Variational AI

국가 캐나다

홈페이지 www.variational.ai

출품 품목 AI 신약개발

회사소개

국문

Variational AI 는 효능, 안전성 및 합성 가능성을 가진 새로운 복합물을

생성함으로써 제약회사가 초기 단계의 신약 개발을 훨씬 더 신속하게 할 수 있도록

지원합니다. Variational AI 의 generative AI 알고리즘은 분자 성분의 예측과 최적화

분야에서 가장 뛰어나며 스탠포드, 구글, MIT 등의 AI 알고리즘보다 우수합니다.

영문

Variational AI helps pharmaceutical companies perform early-stage drug

discovery much more quickly by generating novel compounds with efficacy,

safety, and synthesizability against targets. Our generative AI algorithm is state-

of-the-art in molecular property prediction and optimization, out-performing AI

algorithms from Stanford, Google, MIT, etc.

제품소개

국문

영문 AI for drug discovery


회사명 DarwinAI

국가 캐나다

홈페이지 www.darwinai.com

출품 품목 Artificial Intelligence, Computer Vision, Machine Learning

회사소개

국문

DarwinAI 는 딥러닝 신경 네트워크의 최적화 및 이해를 바탕으로 딥러닝 기술을

시장에 보다 빠르게 출시하였습니다. DarwinAI 가 보유한 독자적인 접근 방식은

자율주행자동차에서 스마트폰에 이르기까지 여러 엣지 디바이스를 사용할 수 있게

해주는 새롭고 보다 효율적인 네트워크를 창출합니다. 또한, 신뢰할 수 있는 AI 를

구축하기 위해 이용자들이 직접 네트워크를 살펴볼 수 있게 합니다. DarwinAI 는

아우디, 인텔, 유럽계 자동차회사, 한국 및 일본의 소비 가전회사, 세계 3 대

항공우주업체 가운데 한 곳 등 전 세계에 포진한 F500 기업과 협력하고 있습니다.

영문

DarwinAI brings deep learning to market faster through optimization and

explainability of deep learning neural networks. Our proprietary approach creates

new, more efficient networks that give a user the ability to deploy the model on

edge devices (from autonomous vehicles to smartphones). In addition, we allow

a user to peak into the network to build AI you can trust that is explainable. We

work with Audi, Intel, and several F500’s across the world in automotive

(European based), consumer electronics (in Korea and Japan), and aerospace

(one of the top 3 in the world).

제품소개

국문

영문


회사명 Cyclica

국가 캐나다

홈페이지 www.cyclicarx.com

출품 품목 AI 신약 개발

회사소개

국문

Cyclica 는 Ligand Design 과 Ligand Express 를 중점으로 구조 기반 및 AI 증강

실리코 디스커버리 플랫폼을 이용하여 다중약리학에 접근하는 최초의 회사입니다.

Cyclica 의 플랫폼은 표적 내외 (on- and off-target) 다중약리학 프로파일에 기반을

둔 화합물과 이 화합물의 속성에 우선 순위를 동시에 두는 방법으로 새로운 화학

물질을 설계하는 데 최적화 되어 있습니다. 업계 내 최고 수준의 플랫폼 및

혁신적인 분권화 파트너십 모델을 지닌 Cyclica 는 환자들의 충족되지 않은 니즈를

보다 정밀하게 맞출 수 있는 의약품을 만들고 있습니다.

영문

Cyclica is the first company to approach polypharmacology with a structure-

based, AI-augmented in silico discovery platform, centred on Ligand Design and

Ligand Express. Cyclica’s platform is suited uniquely to the design of novel,

chemical matter by simultaneously prioritizing compounds based on their on-

and off-target polypharmacological profiles as well as their developmental

properties. With a world-class team that has deep roots in the industry, a first-

in-class platform, and an innovative decentralized partnership model, Cyclica is

creating medicines with greater precision for unmet patient needs.

제품소개

국문

영문 AI in Drug Discovery


회사명 AltumView Systems

국가 캐나다

홈페이지 www.altumview.com

출품 품목 AI, 디지털 헬스, IoT

회사소개

국문

AltumView Systems 는 캐나다 AI 스타트업으로, 기관 혹은 가정 내에서 재활과

노년층 케어서비스를 위한 스마트 비전 기술 및 다양한 IoT 센서 등의 서비스

플랫폼을 개발하는데 중점을 두고 있습니다. AltumView Systems 는 엣지 컴퓨팅 및

AI 알고리즘에 특화돼 있으며, 임베디드 시스템에 최적화 되어 있습니다. 현재까지

전 세계 특허출원은 15 건이며, 미국에서는 8 건이 특허로 등록 되어있습니다.

AltumView Systems 의 제품은 중국, 일본, 캐나다에서 성공적으로 출시되었습니다.

영문

AltumView Systems Inc is a Canadian AI startup, focusing on the development of

smart vision technologies and service platform including many IoT sensors, for

senior care and rehabilitation in institutions and homes. AltumView is specialized

in edge computing and AI algorithms development and optimization for

embedded systems. We have filed more than 15 patents globally with 8

approved in USA. The products have been successfully launched in China, Japan,

and Canada.

제품소개

국문

영문

Cypress visual sensor and medical alert system can: (1) monitor senior’s daily

activities and recommend healthier life style; (2) detect fall and alert caregiver or

loved ones through APP, with privacy preservation through stick figure

animation; (3) perform real-time continuous fall risk assessment for fall

prevention; (4) set restricted zone to manage patients with wandering risk; (5)

recognize gestures such as waving hand to call for help, (6) 2-way audio

communicate. It’s suitable for service providers and system integrator to offer

care at home or institutions.


회사명 Austrianova

국가 태국

홈페이지 www.austrianova.com

출품 품목 Cell encapsulation technology

회사소개

국문

영문

Austrianova is a Business-to-Business (B2B) company that has developed two

technologies that could address some of these areas.

1) Cell-in-a-Box®, allows cells to be implanted in the body and protected from

immune rejection. The capsules are porous so any biologic made by the cells will

be released such as vaccines, cytokines, immunomodulatory molecules,

monoclonal antibodies - we have published peer reviewed papers on most of

these applications. Moreover, we know from clinical trials in other areas of

application of Cell-in-a-Box® that it is safe and efficacious in 27 human patients.

Importantly, Cell-in-a-Box® encapsulated cells can be produced at our GMP

facility and they can be stored at -80c for over 5 years without loss of viability

and shipped across the world.

2) Bac-in-a-Box®, our related encapsulation technology, can protect probiotics

from low pH in the stomach and lead to better re-colonization of the gastric

tract as well as can be freeze dried for easy storage and transport. In addition,

Bac-in-a-Box® has applications for redressing the microbiome balance and for

delivery of oral live bacteria vaccines.

제품소개 국문

영문

1) Cell encapsulation technology for human cells (Cell-in-a-Box) to improve cell

therapies.

2) Cell encapsulation technology bacteria/yeast (Bac-in-a-Box) to allow ambient

storage and to protect from stomach acid for better delivery to instestines


회사명 ACLIRES Bangkok Ltd.

국가 태국

홈페이지 www.aclires.com

출품 품목 Clinical Trial Services

회사소개

국문

영문

ACLIRES International Ltd., with its main operation located in Bangkok, Thailand,

provides high-standard clinical research service, focusing on early phases

especially phase II patient clinical trials in Asia. Internationally trained experts are

delivering the service in English according to ICH-GCP. ACLIRES have been

serving large international pharmaceutical companies as well as small

international biotech companies for more than 12 years.

We have access to large patient populations and can assure fast recruitment

and good patient retention. Our clinical trials are conducted at competitive price

level with efficient trial coordination according to high quality standards. The

data can be used and have been used for US FDA as well as EMA submissions.

ACLIRES is located at Siriraj University Hospital, one of the most prestigious

and largest medical school and teaching hospitals in Thailand. Through this

cooperation, we have access to a large network of experts as well as other

university hospitals. We offer extensive experience in important therapeutic areas

such as infectious diseases, immunology, oncology, metabolic and cardiovascular

diseases. Our in-house research nurses are trained in performing PK/PD. The

ACLIRES team can provide all regulatory support such as EC/IRB submission,

drug and lab kit importation as well as reporting to authorities according to law

and requirements.

제품소개

국문

영문

Clinical Trial Services:

- Regulatory

- Monitoring

- Medical writing

- Research nurses

- Project Management

- Consultation


회사명 Herbanext Laboratories, Inc.

국가 필리핀

홈페이지 www.herbanext.com

출품 품목

회사소개

국문

영문

Herbanext Laboratories, Inc., based in Bago City, Negros Occidental, is the

country's pioneer and leader in the production of standardized herbal extracts.

Founded in 2001 as a small agricultural enterprise focused on the cultivation and

processing of the medicinal mushroom Ganoderma lucidum, Herbanext

underwent major transformation in 2006 expanding to other medicinal plants

and tapping into the country’s vast botanical diversity for the development of

functional and nutraceutical ingredients. Herbanext is an active private sector

proponent of the academe-led drug discovery program funded by the Philippine

Department of Science and Technology (DOST). This state-of-the-art and GMP

accredited facility is now paving the way to an industry shift from the traditional

use of powdered herbs to the use of more potent herbal extracts.

제품소개 국문

영문

Herbanext produces both spray-dried herbal extracts and powdered herbs of

Philippine medicinal plants, such as Lagerstroemia speciosa, Curcuma longa,

Garcinia mangostana, Centella asiatica, Blumea balsamifera, Moringa oleifera, etc.

Herbanext also engages in the production of science-based food supplements,

nutraceuticals, and cosmetics (featured here) including Euphorbia hirta (tawa-

tawa) standardized extract capsules, Turmeric+Piperine tablets (CurCleanse), and

Liquid Stevia Sweetener (Stevia Drops)


회사명 Orich International Traders Inc

국가 필리핀

홈페이지 www.orich.com.ph

출품 품목 Fuctional natural ingredient

회사소개

국문

영문 Functional Ingredients for the beverage and food industry

제품소개

국문

영문

Spray dried Moringa, Graviola leaf extract, magosteen leaf extract, calamansi,

turmeric etc., (also available in dried whole or pulverized) others: Sweet Potato

Chips, flour, banana chips & chocolate barks


회사명 SYNNOVATE PHARMA CORPORATION

국가 필리핀

홈페이지 www.synnovate.com.ph

출품 품목

회사소개

국문

영문

제품소개

국문

영문 Natural products in raw active materials and finished products


회사명 LEONIE AGRI CORP

국가 필리핀

홈페이지 www.leonieagricorp.com

출품 품목

회사소개

국문

영문

제품소개

국문

영문 RAW MATERIALS, FOOD SUPPLE MENTS, POWDERED JUICES TEAS, MUSHROOM

CHIPS


회사명 GreenPlus Corporation

국가 필리핀

홈페이지 www.greenplus.com.ph

출품 품목

회사소개

국문

영문

제품소개

국문

영문 Toll Manufacturer for Food Supplements, Food and Beverage, Personal Care

Products


회사명 Novotech CRO

국가 호주

홈페이지 www.novotech-cro.com

출품 품목

회사소개

국문

영문

Novotech was established in 1996, with offices in 11 locations across the region,

and site partnerships with major health institutions.

Novotech provides clinical development services across all clinical trial phases

and therapeutic areas including: feasibility assessments; ethics committee and

regulatory submissions, data management, statistical analysis, medical

monitoring, safety services, central lab services, report write-up to ICH

requirements, project and vendor management. Novotech obtained the ISO

27001 certification which is the best-known standard in the ISO family providing

requirements for an Information Security Management System. Together with

the ISO 9001 Quality Management system, Novotech aims at the highest IT

security and quality standards for patients and biotechnology companies.

제품소개 국문

영문

Novotech relies on years of experience, in-country knowledge and real-life big

data to identify and propose the best-performing sites and investigators for your

study. Our experience span across numerous therapeutic areas and indications

especially:

- Oncology CRO services, and Immuno-Oncology CRO services

- Infectious diseases and Vaccines CRO services

- Orphan and Rare diseases CRO services

Documents

파트너링 VIP 참석자 배포용 해외 참여기업 리스트 · 1 day ago · 파트너링 VIP 참석자 배포용 회사명 Tubepac SDN